Patient-Reported Outcomes Similar With Extended Natalizumab Dosing Interval - Medpage Today
6/9/2022 12:00:00 AM2 years 10 months ago
by Judy George
by Judy George
NOVA trial looks at 6-week dosing to reduce PML risk
No significant differences emerged in patient-reported outcomes among relapsing-remitting multiple sclerosis (MS) patients who received natalizumab (Tysabri) every 6 weeks (Q6W) versus every 4 weeks … [+4256 chars]
full article...